NPC1L1 and cholestasis: In the GLGC2021, NPC1L1 inhibitors may reduce the risk of the following diseases or symptoms, including: respiratory abnormalities, pancreatic cancer, obstruction of the bile duct, adverse effects caused by opiates and related narcotics during therapeutic use, malposition and malpresentation of the fetus or obstruction, Bladder neck obstruction, hypovolemia, unstable angina (intermediate coronary syndrome), acquired toe deformities, ulcer of the esophagus, coronary atherosclerosis, hypercholesterolemia, disorders of lipoid metabolism, hyperlipidemia, ischemic heart disease.